MacroGenics shares surge 28.50% after-hours after securing $75M in partnership proceeds and exceeding Q3 earnings estimates.

MacroGenics surged 28.50% in after-hours trading following the release of its Q3 2025 earnings and corporate updates. The company secured $75 million in non-dilutive partnership payments from Sanofi and Gilead, extended its cash runway into late 2027, and realigned its pipeline by halting lorigerlimab development in prostate cancer while advancing ovarian cancer trials. Additionally, third-quarter net income of $16.8 million (27 cents per share) and $72.8 million in revenue exceeded Wall Street expectations, reflecting improved operational efficiency and collaboration revenue. These developments underscored strategic progress and financial stability, driving investor optimism.